The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - SERVIER
Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Gregory Michael Cote
Consulting or Advisory Role - BioAtla; C4 Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Foghorn Therapeutics; Ikena Oncology
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - GRAIL (Inst); Roche (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); Celgene (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst)
 
Lia Gore
Stock and Other Ownership Interests - Amgen; Mirati Therapeutics (I); OnKure; Sanofi
Consulting or Advisory Role - Amgen; Janssen Oncology; Novartis; OnKure; Pfizer; Roche/Genentech; Syndax
Patents, Royalties, Other Intellectual Property - Patent held for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia.
(OPTIONAL) Uncompensated Relationships - Kestrel Therapeutics (I)
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Agios (Inst); AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck
 
Anthony Paul Conley
Consulting or Advisory Role - AADi; Applied Clinical Intelligence; Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Chordoma Foundation (Inst); EpicentRx (Inst); Ignyta (Inst); InhibRx (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MedImmune (Inst); NantHealth (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Genentech
 
Diego A. Gianolio
Employment - SERVIER
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Patents with Sanofi
Travel, Accommodations, Expenses - Servier
 
Zhe Qu
Employment - SERVIER
 
Camelia Gliser
No Relationships to Disclose
 
Shuchi Sumant Pandya
Employment - SERVIER
 
Jonathan C. Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER